Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma

Cancer Science

Volumn 104, Issue 3, 2013, Pages 375-382

  Xiu, Peng ^a   Dong, Xuesong ^b   Dong, Xiaofeng ^a   Xu, Zongzhen ^a   Zhu, Huaqiang ^d   Liu, Feng ^a   Wei, Zheng ^b   Zhai, Bo ^b   Kanwar, Jagat R ^e   Jiang, Hongchi ^b   Li, Jie ^a   Sun, Xueying ^b,c  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c THE UNIVERSITY OF AUCKLAND   (New Zealand)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^e DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CLUSTERIN; GLYCOGEN SYNTHASE KINASE 3BETA; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; SECRETORY CLUSTERIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CLUSTERIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84874463929     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12088     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-22.
3. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1: 227-35.
4. Kato T, Nagata N, Fujii M et al. Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study. Anticancer Res 2011; 31: 4657-64.
5. Sanoff HK, Carpenter WR, Martin CF et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012; 104: 211-27.
6. Pera M, Gallego R, Montagut C et al. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol 2012; 23: 664-70.
7. Wang Z, Zhou J, Fan J et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs 2009; 18: 1595-604.
8. Taieb J, Bonyhay L, Golli L et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003; 98: 2664-70.
9. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-903.
10. Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem 1983; 258: 7714-20.
11. Djeu JY, Wei S. Clusterin and chemoresistance. Adv Cancer Res 2009; 105: 77-92.
12. Aigelsreiter A, Janig E, Sostaric J et al. Clusterin expression in cholestasis, hepatocellular carcinoma and liver fibrosis. Histopathology 2009; 54: 561-70.
13. Kang YK, Hong SW, Lee H, Kim WH. Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol 2004; 35: 1340-46.
14. Lau SH, Sham JS, Xie D et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006; 25: 1242-50.
15. Mukherji D, Eichholz A, De Bono JS. Management of metastatic castration-resistant prostate cancer: recent advances. Drugs 2012; 72: 1011-28.
16. Jin J, Kim JM, Hur YS et al. Clinical significance of clusterin expression in pancreatic adenocarcinoma. World J Surg Oncol 2012; 10: 146.
17. Zhang D, Sun B, Zhao X et al. Secreted CLU is associated with the initiation of triple-negative breast cancer. Cancer Biol Ther 2012; 13: 321-9.
18. Rodriguez-Pineiro AM, Garcia-Lorenzo A, Blanco-Prieto S et al. Secreted clusterin in colon tumor cell models and its potential as diagnostic marker for colorectal cancer. Cancer Invest 2012; 30: 72-8.
19. Hassan MK, Watari H, Han Y et al. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res 2011; 30: 113.
20. Lokamani I, Looi ML, Ali SA, Dali AZ, Jamal R. Clusterin as a potential marker in distinguishing cervical neoplasia. Anal Quant Cytol Histol 2011; 33: 223-8.
21. Bi J, Guo AL, Lai YR et al. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. Neoplasma 2010; 57: 191-7.
22. Hazzaa SM, Elashry OM, Afifi IK. Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res 2010; 16: 101-9.
23. He LR, Liu MZ, Li BK et al. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci 2009; 100: 2354-60.
24. Li H, Liu S, Zhu X, Yang S, Xiang J, Chen H. Clusterin immunoexpression and its clinical significance in patients with non-small cell lung cancer. Lung 2010; 188: 423-31.
25. Wang Y, Liu YH, Mai SJ et al. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis. J Gastroenterol Hepatol 2010; 25: 1123-8.
26. Nafee AM, Pasha HF, Abd El Aal SM, Mostafa NA. Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma. Clin Biochem 2012; 45: 1070-74.
27. Lamoureux F, Thomas C, Yin MJ et al. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res 2011; 71: 5838-49.
28. Saad F, Hotte S, North S et al. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 2011; 17: 5765-73.
29. Laskin JJ, Nicholas G, Lee C et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 2012; 7: 579-86.
30. Li J, Tan H, Dong X et al. Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig Liver Dis 2007; 39: 557-65.
31. He C, Sun XP, Qiao H et al. Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin to treat hepatocellular carcinoma. Cancer Sci 2012; 103: 528-34.
32. Wang J, Ma Y, Jiang H et al. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice. J Hepatol 2011; 55: 359-68.
33. Zhang F, Suarez G, Sha J, Sierra JC, Peterson JW, Chopra AK. Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells. Cell Signal 2009; 21: 1085-99.
34. Radisavljevic Z. AKT as locus of cancer multidrug resistance and fragility. J Cell Physiol 2013; 228: 671-4.
35. Lee KB, Jeon JH, Choi I, Kwon OY, Yu K, You KH. Clusterin, a novel modulator of TGF-beta signaling, is involved in Smad2/3 stability. Biochem Biophys Res Commun 2008; 366: 905-9.
36. Leskov KS, Araki S, Lavik JP et al. CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor. J Biol Chem 2011; 286: 40083-90.
37. Goetz EM, Shankar B, Zou Y et al. ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability. Oncogene 2011; 30: 3745-54.
38. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005; 7: 909-15.
39. Shim YJ, Kang BH, Choi BK, Park IS, Min BH. Clusterin induces the secretion of TNF-alpha and the chemotactic migration of macrophages. Biochem Biophys Res Commun 2012; 422: 200-205.
40. Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol 2011; 7: 1149-67.
41. Shim YJ, Kang BH, Jeon HS et al. Clusterin induces matrix metalloproteinase-9 expression via ERK1/2 and PI3K/Akt/NF-κB pathways in monocytes/macrophages. J Leukoc Biol 2011; 90: 761-9.
42. Beurel E, Blivet-Van Eggelpoel MJ, Kornprobst M et al. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells. Biochem Pharmacol 2009; 77: 54-65.
43. El Fajoui Z, Toscano F, Jacquemin G et al. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology 2011; 141: 663-73.
44. Patterson SG, Wei S, Chen X et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006; 25: 6113-22.
45. Sowery RD, Hadaschik BA, So AI et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008; 102: 389-97.
46. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000; 60: 2547-54.
47. Zellweger T, Chi K, Miyake H et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002; 8: 3276-84.